Novo Nordisk’s Bittersweet Victory: EU Backs New Wegovy Forms as Shares Slump and Competition Inte
Despite two CHMP recommendations for oral and high-dose Wegovy in May, Novo Nordisk stock is down 40% over…
Novo Nordisk Races to Close the Efficacy Gap: EU Backs Oral Wegovy as Lilly Posts 28.3% Weight Loss
EU regulator recommends oral and high-dose Wegovy as Novo Nordisk counters Eli Lilly’s 28.3% weight-loss Retatrutide, but efficacy…
Novo Nordisk Turns the Page: EU Backs Oral Wegovy as Liver Disease Data and a DKK 11.2bn Buyback Lif
Novo Nordisk launches DKK 11.2B buyback, receives EU approval for two new Wegovy formulations, posts strong oral tablet…
Novo Nordisk Turns a Corner: EU Panel Backs Both Oral and High-Dose Wegovy as US Sales Surprise
European Medicines Agency backs two Wegovy formulations; oral tablet becomes first GLP-1 pill for weight loss in EU.…